{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:36:54Z","timestamp":1792712214267,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13555-025-01386-2","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T13:25:40Z","timestamp":1745587540000},"page":"1467-1485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapies"],"prefix":"10.1007","volume":"15","author":[{"given":"Melinda J.","family":"Gooderham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Miller-Monthrope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ringuet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Turchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"issue":"1 suppl","key":"1386_CR1","doi-asserted-by":"publisher","first-page":"6S","DOI":"10.1177\/1203475418803626","volume":"22","author":"MG Kirchhof","year":"2018","unstructured":"Kirchhof MG, Landells I, Lynde CW, Gooderham MJ, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section I: pathophysiology of atopic dermatitis and implications for systemic therapy. J Cutan Med Surg. 2018;22(1 suppl):6S-9S.","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"1386_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/all.12112","volume":"68","author":"D Garmhausen","year":"2013","unstructured":"Garmhausen D, Hagemann T, Bieber T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013;68(4):498\u2013506.","journal-title":"Allergy"},{"issue":"1","key":"1386_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0190-9622(94)70004-4","volume":"30","author":"J Kay","year":"1994","unstructured":"Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30(1):35\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1386_CR4","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.jaad.2018.05.1241","volume":"80","author":"HH Lee","year":"2019","unstructured":"Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1386_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"1386_CR6","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s12325-021-01630-z","volume":"38","author":"SG Kwatra","year":"2021","unstructured":"Kwatra SG, Gruben D, Fung S, DiBonaventura M. Psychosocial comorbidities and health status among adults with moderate-to-severe atopic dermatitis: a 2017 US national health and wellness survey analysis. Adv Ther. 2021;38(3):1627\u201337.","journal-title":"Adv Ther"},{"issue":"6","key":"1386_CR7","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393.","journal-title":"Allergy"},{"issue":"4","key":"1386_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417\u201328.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"1386_CR9","first-page":"274","volume":"132","author":"DK Chu","year":"2023","unstructured":"Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2023;132(2):274\u2013312.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1386_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1386_CR11","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/jdv.18429","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1386_CR12","unstructured":"Pfizer Canada Inc. EUCRISA\u00ae (crisaborole). Product Monograph. Kirkland: 2021."},{"key":"1386_CR13","unstructured":"Incyte Corporation and Innomar Strategies. Opzelura\u00ae (ruxolitinib cream). Product Monograph. Oakville: 2024."},{"issue":"1","key":"1386_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11\u20138.","journal-title":"Exp Dermatol"},{"issue":"4","key":"1386_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/bjd.21615","volume":"187","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Bissonnette R, Paller AS, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): a clinical outcome measure for the severity of atopic dermatitis. Br J Dermatol. 2022;187(4):531\u20138.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1386_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"1386_CR17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139.","journal-title":"Arch Dermatol"},{"issue":"4","key":"1386_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1386_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bjd.20783","volume":"186","author":"J Puelles","year":"2022","unstructured":"Puelles J, Fofana F, Rodriguez D, et al. Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis. Br J Dermatol. 2022;186(2):285\u201394.","journal-title":"Br J Dermatol"},{"key":"1386_CR20","doi-asserted-by":"crossref","unstructured":"Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23\u201331.","DOI":"10.1159\/000247298"},{"issue":"4","key":"1386_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","volume":"77","author":"EL Simpson","year":"2017","unstructured":"Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623\u201333.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1386_CR22","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/1203475418803628","volume":"22","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutan Med Surg. 2018;22(1):10S-S16.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"1386_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jaci.2017.01.029","volume":"140","author":"A Heratizadeh","year":"2017","unstructured":"Heratizadeh A, Werfel T, Wollenberg A, et al. Effects of structured patient education in adults with atopic dermatitis: multicenter randomized controlled trial. J Allergy Clin Immunol. 2017;140(3):845\u201353.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1386_CR24","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/bjd.15602","volume":"177","author":"EJ van Zuuren","year":"2017","unstructured":"van Zuuren EJ, Fedorowicz Z, Arents BWM. Emollients and moisturizers for eczema: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol. 2017;177(5):1256\u201371.","journal-title":"Br J Dermatol"},{"key":"1386_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s13671-013-0057-7","volume":"2","author":"JJ Schoch","year":"2013","unstructured":"Schoch JJ, Davis DMR. A practical guide to outpatient wet dressings for pediatric atopic dermatitis. Curr Derm Rep. 2013;2:212\u20135.","journal-title":"Curr Derm Rep"},{"issue":"1","key":"1386_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jaad.2011.06.025","volume":"67","author":"TS Dabade","year":"2012","unstructured":"Dabade TS, Davis DM, Wetter DA, et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30\u00a0years at Mayo Clinic. J Am Acad Dermatol. 2012;67(1):100\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1386_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2174\/1573396316999200820163434","volume":"17","author":"YB Yang","year":"2021","unstructured":"Yang YB, Gohari A, Lam J. Brief academic review and clinical practice guidelines for pediatric atopic dermatitis. Curr Pediatr Rev. 2021;17(3):229\u201337.","journal-title":"Curr Pediatr Rev"},{"issue":"6","key":"1386_CR28","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1210\/jc.2015-1218","volume":"100","author":"LH Broersen","year":"2015","unstructured":"Broersen LH, Pereira AM, Jorgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(6):2171\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1386_CR29","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","volume":"152","author":"DK Chu","year":"2023","unstructured":"Chu DK, Chu AWL, Rayner DG, et al. Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1493\u2013519.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1386_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2014.11.024","volume":"72","author":"T Hajar","year":"2015","unstructured":"Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal (\u201csteroid addiction\u201d) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1386_CR31","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1080\/09546634.2021.1882659","volume":"33","author":"J Hwang","year":"2022","unstructured":"Hwang J, Lio PA. Topical corticosteroid withdrawal ('steroid addiction\u2019): an update of a systematic review. J Dermatolog Treat. 2022;33(3):1293\u20138.","journal-title":"J Dermatolog Treat"},{"key":"1386_CR32","unstructured":"LEO Pharma Inc. PROTOPIC\u00ae (tacrolimus). Product Monograph. Toronto: 2022."},{"key":"1386_CR33","unstructured":"Bausch Health Canada Inc. ELIDEL\u00ae (pimecrolimus). Product Monograph. Laval: 2020."},{"issue":"3","key":"1386_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3109\/09546630903401470","volume":"21","author":"SL Chen","year":"2010","unstructured":"Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010;21(3):144\u201356.","journal-title":"J Dermatolog Treat"},{"key":"1386_CR35","doi-asserted-by":"publisher","first-page":"adv00890","DOI":"10.2340\/actadv.v103.6525","volume":"103","author":"D Amiri","year":"2023","unstructured":"Amiri D, Schwarz CW, Gether L, Skov L. Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review. Acta Derm Venereol. 2023;103:adv00890.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1386_CR36","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494\u2013503.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1386_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","volume":"7","author":"N Devasenapathy","year":"2023","unstructured":"Devasenapathy N, Chu A, Wong M, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2023;7(1):13\u201325.","journal-title":"Lancet Child Adolesc Health"},{"issue":"10","key":"1386_CR38","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2020.2240","volume":"156","author":"MM Asgari","year":"2020","unstructured":"Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP Jr. Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol. 2020;156(10):1066\u201373.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1386_CR39","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bjd.16046","volume":"178","author":"A Ahmed","year":"2018","unstructured":"Ahmed A, Solman L, Williams HC. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal. Br J Dermatol. 2018;178(3):659\u201362.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1386_CR40","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jaad.2017.06.010","volume":"77","author":"LF Eichenfield","year":"2017","unstructured":"Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1386_CR41","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.jaad.2018.10.054","volume":"80","author":"C Pao-Ling Lin","year":"2019","unstructured":"Pao-Ling Lin C, Gordon S, Her MJ, Rosmarin D. A retrospective study: application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor. J Am Acad Dermatol. 2019;80(5):1451\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1386_CR42","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/ijd.17139","volume":"63","author":"C Ma","year":"2024","unstructured":"Ma C, Sun J, Liu Z, Zhang C. Real-world efficacy of 2% crisaborole ointment on chronic hyperplasia lesions in 49 patients with atopic dermatitis. Int J Dermatol. 2024;63(10):1375\u201382.","journal-title":"Int J Dermatol"},{"key":"1386_CR43","unstructured":"Arcutis Biotherapeutics. ZORYVE\u00ae (roflumilast). Full Prescribing Information. Westlake Village: 2024."},{"key":"1386_CR44","unstructured":"Arcutis Canada. ZORYVE\u00ae (roflumilast cream). Product Monograph. North York: 2025."},{"issue":"11","key":"1386_CR45","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamadermatol.2024.3121","volume":"160","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials. JAMA Dermatol. 2024;160(11):1161\u201370.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1386_CR46","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","volume":"145","author":"BS Kim","year":"2020","unstructured":"Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME. Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572\u201382.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1386_CR47","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","volume":"82","author":"BS Kim","year":"2020","unstructured":"Kim BS, Sun K, Papp K, Venturanza M, Nasir A, Kuligowski ME. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase\u00a02, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020;82(6):1305\u201313.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1386_CR48","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase\u00a03 studies. J Am Acad Dermatol. 2023;88(5):1008\u201316.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1386_CR49","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.anai.2022.12.033","volume":"130","author":"DYM Leung","year":"2023","unstructured":"Leung DYM, Paller AS, Zaenglein AL, et al. Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis. Ann Allergy Asthma Immunol. 2023;130(4):500\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1386_CR50","unstructured":"Eichenfield LF, Stein Gold LF, Simpson EL, et al. A phase 3 study of ruxolitinib cream in children aged 2\u2013<12 years with atopic dermatitis (TRuE-AD3): 8-week analysis. In: Presented at 32nd European Academy of Dermatology and Venereology (EADV) Congress; 2023 October 11\u201314; Berlin"},{"key":"1386_CR51","unstructured":"US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed Feb 2, 2024."},{"issue":"3","key":"1386_CR52","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","volume":"46","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. 2016;46(3):261\u201371.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"1386_CR53","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"1386_CR54","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-023-00840-1","volume":"25","author":"W Hu","year":"2024","unstructured":"Hu W, Thornton M, Livingston RA. Real-world use of ruxolitinib cream: safety analysis at 1\u00a0year. Am J Clin Dermatol. 2024;25(2):327\u201332.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1386_CR55","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1111\/jdv.15709","volume":"33","author":"C Vestergaard","year":"2019","unstructured":"Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644\u201359.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1386_CR56","unstructured":"Merck Canada Inc. DIPROSONE\u00ae (betamethasone dipropionate). Product Monograph. Kirkland: 2017."},{"issue":"3","key":"1386_CR57","first-page":"CD013356","volume":"3","author":"SJ Lax","year":"2022","unstructured":"Lax SJ, Harvey J, Axon E, et al. Strategies for using topical corticosteroids in children and adults with eczema. Cochrane Database Syst Rev. 2022;3(3):CD013356.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1386_CR58","first-page":"CD012119","volume":"2","author":"EJ van Zuuren","year":"2017","unstructured":"van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2(2):CD012119.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1 Suppl","key":"1386_CR59","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1067\/mjd.2001.109812","volume":"44","author":"S Kang","year":"2001","unstructured":"Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44(1 Suppl):S58-64.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1386_CR60","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jaad.2023.04.029","volume":"89","author":"NS Stefanko","year":"2023","unstructured":"Stefanko NS, Quan VL, Chovatiya R. Efficacy, safety, and treatment patterns of ruxolitinib 1.5% cream in adult atopic dermatitis: a single center retrospective study. J Am Acad Dermatol. 2023;89(2):415\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1386_CR61","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s13555-024-01219-8","volume":"14","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Kircik L, Blauvelt A, et al. Ruxolitinib cream in adolescents\/adults with atopic dermatitis meeting severity thresholds for systemic therapy: exploratory analysis of pooled results from two phase 3 studies. Dermatol Ther (Heidelb). 2024;14(8):2139\u201351.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1386_CR62","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2133.2010.10030.x","volume":"164","author":"J Schmitt","year":"2011","unstructured":"Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164(2):415\u201328.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1386_CR63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1399-3038.2008.00735.x","volume":"20","author":"EJ Glazenburg","year":"2009","unstructured":"Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol. 2009;20(1):59\u201366.","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"1386_CR64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/09546630410033781","volume":"15","author":"TA Luger","year":"2004","unstructured":"Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004;15(3):169\u201378.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1386_CR65","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000078462","volume":"208","author":"M Meurer","year":"2004","unstructured":"Meurer M, Fartasch M, Albrecht G, et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology. 2004;208(4):365\u201372.","journal-title":"Dermatology"},{"issue":"4","key":"1386_CR66","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1542\/peds.2014-1990","volume":"135","author":"B Sigurgeirsson","year":"2015","unstructured":"Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597\u2013606.","journal-title":"Pediatrics"},{"issue":"1 Suppl","key":"1386_CR67","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1067\/mjd.2001.109813","volume":"44","author":"A Paller","year":"2001","unstructured":"Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44(1 Suppl):S47-57.","journal-title":"J Am Acad Dermatol"},{"issue":"1 Suppl","key":"1386_CR68","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1067\/mjd.2001.109810","volume":"44","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001;44(1 Suppl):S28-38.","journal-title":"J Am Acad Dermatol"},{"issue":"1 Suppl","key":"1386_CR69","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1067\/mjd.2001.109817","volume":"44","author":"NA Soter","year":"2001","unstructured":"Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44(1 Suppl):S39-46.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1386_CR70","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1067\/mai.2002.121832","volume":"109","author":"S Reitamo","year":"2002","unstructured":"Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002;109(3):547\u201355.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1386_CR71","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1067\/mai.2002.121831","volume":"109","author":"S Reitamo","year":"2002","unstructured":"Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109(3):539\u201346.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01386-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T17:03:26Z","timestamp":1747760606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01386-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01386-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Melinda J. Gooderham has served as a principal investigator for AbbVie, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Aristea, Aslan, Bausch Health, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Cara Therapeutics, Coherus Biosciences, Dermira, Eli Lilly, Galderma SA, GlaxoSmithKline, Incyte Corporation, InMagene, JAMP, Janssen, LEO Pharma, MedImmune, Meiji, MoonLake, Nektar Therapeutics, Nimbus, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda Pharmaceutical Company, Tarsus, UCB, Ventyx, and Vyne; a consultant for AbbVie, Amgen, Apogee, Aslan, Bausch Health, Boehringer Ingelheim International GmbH, Eli Lilly, Janssen, Novartis Pharmaceuticals, Sanofi Genzyme, Sun Pharma, and UCB; an advisory board member for AbbVie, Amgen, Apogee, Arena Pharmaceuticals, Asana BioSciences, Aslan, Bausch Health, Boehringer Ingelheim International GmbH, Eli Lilly, Galderma SA, Incyte Corporation, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Union; and a paid speaker for AbbVie, Amgen, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim International GmbH, Eli Lilly, Galderma SA, Janssen, JAMP, LEO Pharma, L\u2019Or\u00e9al, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB. H. Chih-ho Hong has served as a speaker, advisor, consultant, and\/or investigator for AbbVie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cutanea, Dermira, Dermavant, DS Biopharma, Eli Lilly, Galderma, GlaxoSmithKline, Incyte Corporation, Janssen, LEO Pharma, Medimmune, Merck, Mirimar, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Roche, and UCB. Charles Lynde has served as a speaker and\/or consultant for AbbVie, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Dermavant, Eli Lilly, Fresnius Kabi, Galderma, GlaxoSmithKline, Incyte Corporation, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L\u2019Or\u00e9al, Medexus, MedX, Merck, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, Sun Pharma, TEVA, Tribute, UCB, Valeant, Viatris, and Volo Health and has served as a principal investigator for AbbVie, Acelyrin, Akros, Altius, Amgen, Aralez, Arcutis, Avillion, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, Concert, Dermavant, Devonian, Eli Lilly, Evelo, Galderma, GlaxoSmithKline, Incyte Corporation, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L\u2019Or\u00e9al, Medexus, MedX, Merck, MoonLake, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, Sun Pharma, TEVA, Tribute, UCB, Valeant, Viatris, and Volo Health. Kim A. Papp has received honoraria and\/or grants as a consultant, speaker, investigator, or scientific officer from AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DICE Pharmaceuticals, DICE Therapeutics, Eli Lilly and Company, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte Corporation, Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB Pharma, and Zai Lab. Jensen Yeung has served as a consultant, investigator, or speaker or received honoraria from AbbVie, Amgen, Arcutis, Apogee, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Fresenius Kabi, Galderma, Incyte Corporation, JAMP Pharma, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, and UCB. Harvey Lui has served as an advisor, consultant, investigator, and\/or speaker for AbbVie, Incyte Corporation, L\u2019Or\u00e9al, Novartis, and Vita Imaging. Yvette Miller-Monthrope has served as an advisor, consultant, and\/or speaker for AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Fresenius Kabi, Galderma, Incyte Corporation, Janssen, Sanofi, Sun Pharma, Novartis, and UCB. Julien Ringuet has served as an advisor, consultant, and\/or speaker for AbbVie, Amgen, Apogee, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, Incyte Corporation, Janssen, LEO Pharma, L\u2019Or\u00e9al, NKS Health, Novartis, Organon, Pfizer, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB and served as an investigator for AbbVie, Alumis, Amgen, Aristea, Aslan, Bristol Myers Squibb, Celgene, Concert Pharmaceuticals, CorEvitas, DICE Therapeutics, Incyte Corporation, Innovaderm, Janssen, LEO Pharma, Merck, Pfizer, Sanofi-Genzyme, Sun Pharma, and UCB. Irina Turchin has served as a speaker, advisor, consultant, or investigator for AbbVie, Amgen, Arcutis, Aristea, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galderma, Horizon Therapeutics, Incyte Corporation, Janssen, Kiniksa, LEO Pharma, Mallinckrodt, MoonLake, Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and Ventyx Biosciences. Vimal H. Prajapati has served as an advisor, consultant, and\/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, Cipher, Concert, CorEvitas, Eczema Society of Canada, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte Corporation, JAMP Pharma, Janssen, Johnson & Johnson, LEO Pharma, Medexus, Novartis, Organon, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, UCB, and Valeant; served as an investigator for AbbVie, AnaptysBio, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte Corporation, Janssen, LEO Pharma, Meiji Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, and UCB; and received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}